The present invention relates to the use of antibodies against S100A7 protein for the prevention and/or treatment of cancer or a disease associated to an undesired angiogenesis or a disease associated with inflammation; and to methods and kits for diagnosing and determining the prognostic of said diseases in vitro and in vivo by means of detecting levels of S100A7 in a biofluid, preferably with an antibody. The invention also relates to specific anti-S100A7 monoclonal antibodies, hybridoma cell lines producing them and method for obtaining them, as well as pharmaceutical compositions and conjugates containing them.